United Therapeutics reported third-quarter earnings of $5.71 per share, missing the $5.85 consensus by 2.4% and falling 20.3% from a year ago. On the surface, that looks like a soft quarter. The revenue line tells a different story. Sales reached a record $832.5 million, beating the $783.33 million consensus by 6.3% and growing 4.1% year over year. More important, revenue broke out of a flat stretch: the company had posted roughly $790 million in the fourth quarter of 2025, $782 million in the first quarter and about $783 million in the second quarter. That is the central tension. A one-time acquisition charge drove the EPS miss, while the commercial business showed its first real reacceleration in a year.

The miss deserves scrutiny, but mostly because of where it came from. Research and development expense more than doubled to $279.2 million. Nearly all of the increase sat in the 'other' category, which jumped to $130.0 million from $4.8 million on in-process R&D tied to the Thymmune asset acquisition. Because that charge is nondeductible for tax purposes, it also pushed the effective tax rate to 31% from 23%, compounding the hit to net income. Two items worked in the other direction. A $66.5 million reversal of the Sandoz litigation accrual lowered SG&A, and gains on equity securities lifted other income to $34.2 million. Interest income fell to $33.7 million from $46.4 million as the company sold securities to fund roughly $2 billion in accelerated buybacks. Those repurchases also cut the diluted share count to 45.3 million from 47.3 million. These are GAAP figures. The underlying operating performance was better than the bottom line suggests, though the quarter carried distortions on both sides.

Beneath the headline, product mix kept shifting. Tyvaso DPI grew 13% to $378.5 million, mostly on volume, and Orenitram rose 11% to $145.0 million. Nebulized Tyvaso fell 12% and Remodulin slipped 3%. The company acknowledged that competitive therapies weighed on Nebulized Tyvaso, Tyvaso DPI and Remodulin. On the call, management said total Tyvaso revenue reached a record $504 million, compared with $453 million in the second quarter and $458 million in the first, and stressed that inventory or seasonal effects did not help. Demand indicators also improved. Referrals inflected from mid-September and topped 1,000 for a single UT product in October, a record. Roughly one in three new DPI patients is now reaching higher doses, about double the prior rate. Management credited the salesforce it doubled in July, which explains the 45% jump in sales and marketing expense, and said the revenue benefit should show up in the fourth quarter and 2027.

The biggest strategic development was the court win and Liquidia settlement. Together they remove PH-ILD from Yutrepia's label and bar its promotion, leaving Tyvaso largely uncontested in that indication. Management, however, expects only moderate near-term switching back from Yutrepia. The company also bought out the Arena royalty on ralinepag ahead of its June 24, 2027 PDUFA date, a signal of confidence. The pipeline gave bears legitimate ammunition, though:

• The Tresmi NDA, promised for a 2026 filing, slipped to 2027 after the FDA requested more data.
• Ralinepag's API supplier carries an OAI compliance status that could threaten the PDUFA timeline, although management cited contingencies.
• The FDA said a bioequivalence study is insufficient for the ralinepag triple-combination pill, leaving that program stalled.

The company also did not reinstate formal 2026 revenue guidance or explicitly update its $4 billion end-2027 run-rate target for the base business.

The market setup is more complicated than the EPS miss implies. Shares entered the report at $601.32, up 19.1% since the opening after the August report. That left the stock 12.9% above its 200-day moving average and just 1.4% below the 52-week high of $609.99 set on October 30. The stock had rallied 28.2% off its September 24 low, largely on the litigation outcome, so a good part of the commercial recovery was already priced in. Investor sentiment remained positive but softened modestly, slipping to 0.17 from 0.22. Price and AVWAP trend readings are positive, while momentum has turned negative, consistent with a stock that has run hard into the print.

Management's tone shifted noticeably. In the second quarter it called results 'below our expectations' and declined to reaffirm guidance. This quarter it described its 'best quarter ever' and said the company is entering 2027 with substantially more momentum. A fresh $2 billion buyback authorization, backed by $3.54 billion in cash and investments, reinforces that confidence.

The bottom line is that United Therapeutics' EPS miss is largely an accounting artifact of the Thymmune charge and a higher tax rate. The more meaningful news is a record revenue quarter, a clear Tyvaso reacceleration and a much-improved competitive position in PH-ILD. Offsetting that are real pipeline slippage and a stock that already trades near its highs, which leaves the fourth quarter as the test of whether record referrals turn into the revenue growth management is now promising.